UBS Maintains Neutral on Solventum, Lowers Price Target to $78

Benzinga Newsdesk www.benzinga.com Negative 66.7%

Neg 66.7% Neu 0% Pos 0%

UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Neutral and lowers the price target from $82 to $78.

Comments

No comments yet. Be the first!